Copyright © 2024 Research Nester. All Rights Reserved
Norepinephrine Drug Market size was over USD 391.26 million in 2023 and is projected to reach USD 1.72 billion by 2036, growing at around 12.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of norepinephrine drug is assessed at USD 429.13 million.
The market is growing at a stable rate owing to the rising prevalence of low blood pressure condition globally, along with the improved efficacy and predictive pharmacological properties of norepinephrine drug. On the other hand, the rapidly increasing geriatric population is driving the norepinephrine drug market growth further.
Growth Drivers
Exceptional properties of norepinephrine drug
Norepinephrine drug has some exceptional advantages over other alpha-adrenergic agonists, it is considered to have more predictive pharmaceutical properties. This predictive quality, combined with some of its beta-adrenergic agonist (which improves cardiac function comparative to pure alpha-adrenergic agonists), makes norepinephrine a widely used sympathomimetic drug. It is commonly used in intensive care units to treat hypotension. Additionally, it is the first-line agent for treating hypotension. This advantage is anticipated to provide lucrative business opportunities for norepinephrine drug market during the forecast period.
Surge in geriatric individuals to boost the norepinephrine drug market
According to a 2017 UN report on World Population Ageing, the global population aged 60 years or over totalled 962 million in 2017, more than twice as large as in 1980 when there were 382 million older persons worldwide. The number of geriatric individuals is expected to double again by 2050 when it is projected to reach nearly 2.1 billion.
Aged individuals are more prone to the risk of low blood pressure, and at present, the population of geriatric individuals in most of the developed economies along with developing nations is increasing at a significant rate. The risk of hypotension normally increases with age due to the decline in blood flow to the heart, muscle and the brain, which often result in the plaque build-up in blood vessels. Hence, the rise in geriatric population is estimated to contribute towards the market demand for norepinephrine drug in future.
Challenges
Side Effects of Drug to Hamper the Market Growth
Drugs are given to save patients from life-threatening conditions and are used to deliver viability to serious condition patients. Except that there are a few major side effects associated with the norepinephrine drug present in the norepinephrine drug market. These might consist of sudden numbness, weakness, uneven heart rate, blue lips or fingernails, mottled skin, trouble breathing, problem with speech, severe headache, blurred vision and others. Moreover, stopping the norepinephrine drug might lead to the recurrence of low blood pressure (hypotension). On account of these, the market for the norepinephrine drugs is estimated to observe limited growth in future.
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
12.1% |
|
Base Year Market Size (2023) |
USD 391.26 million |
|
Forecast Year Market Size (2036) |
USD 1.72 billion |
|
Regional Scope |
|
The norepinephrine drug market is segmented by product, by application, by end-user, and by region. Based on the end-user, the norepinephrine market is segmented into hospitals, private clinics, ambulatory surgery centers, and others, out of which, the hospital segment accounts for the largest market share on account of the increase in the number of elderly patients every year. Elderly in-patients are higher than the patients in-home care settings owing to the intensive monitoring and caring routine of elderly patients at hospitals. Norepinephrine is a strong drug and excellent at increasing systematic vascular resistance therefore, it is globally used as first-line agents to treat hypotension in patients with acute circulatory failure. Norepinephrine is considered to be better than dopamine owing to its properties and fewer adverse side-effects. All these factors are expected to thrive in the norepinephrine market in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Application Type |
|
|
By End-User Type |
|
On the basis of regional analysis, the global norepinephrine drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Based on the region, the markets in North America industry is likely to account for largest revenue share by 2036, propelled by rising geriatric population in the region. Additionally, the early adoption of cutting edge technology and innovations along with the considerable presence of the key market player in the region are further estimated to boost the market growth. On the other hand, norepinephrine market in Asia-Pacific region is likely to show an upward growth in the years to come. This can be accredited to the rising population of geriatric people in the region.
April 10, 2020: American Society of Anesthesiologists (ASA) threw some spotlight on most urgently on the ICU sedative propofol. The group further added in an open letter to the FDA the following statement - "With the increased demand for this drug and the number of COVID-19 positive patients needing ventilators, we can only anticipate that this will soon be in shortage". The society pointed to an increased need for resuscitative drugs including norepinephrine due to the COVID-19 crisis.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?